Known targets — ChEMBL curated mechanism
ACHECHRM1DRD1DRD2HTR2AHTR2BHTR2CMAOA
The experimentally established mechanism targets of Minaprine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 5/20 | 0.98 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.98 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | CNR1 | P21554 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Minaprine SCHEMBL124092 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAACHECHRM1CYP1A2 | |
| Minaprine SCHEMBL49371 | 0.99 | ACHE (1.00) | CYP3A4LMNAACHECHRM1CYP1A2 | |
| Minaprine SCHEMBL124093 | 0.97 | ACHE (0.95) | CYP3A4LMNAACHECHRM1CYP1A2 | |
| SCHEMBL1752978 | 0.89 | LMNA (0.80) | CYP3A4LMNAACHECHRM1CYP1A2 | |
| Moxiraprine SCHEMBL635650 | 0.87 | ACHE (0.80) | CYP3A4LMNAACHECHRM1CYP1A2 | |
| SCHEMBL1752900 | 0.87 | ACHE (1.00) | CYP3A4LMNAACHECHRM1CYP1A2 | |
| SCHEMBL31759026 | 0.87 | ACHE (0.82) | CYP3A4LMNAACHECHRM1CYP1A2 | |
| SCHEMBL10744195 | 0.87 | ACHE (0.78) | CYP3A4LMNAACHECHRM1CYP1A2 | |
| SCHEMBL10748868 | 0.85 | ACHE (0.77) | CYP3A4LMNAACHECHRM1CYP1A2 | |
| SCHEMBL14069119 | 0.85 | ACHE (0.75) | CYP3A4LMNAACHECHRM1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803559-B1 | Protein aggregation regulators | THE REGENTS OF THE UNIVERSITY OF CA (US) | 2010-09-28 | — | — | US | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2024-07-25 | — | — | US | disclosed |
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| US-11517575-B2 | Use of minaprine to reduce tumor growth | INSTITUT GUSTAVE ROUSSY (FR) | 2022-12-06 | — | — | US | disclosed |
| US-6323236-B2 | PSYCHOLOGICAL DISORDERS | UNIVERSITY OF CINCINNATI | 2001-11-27 | — | — | US | disclosed |
| US-20010023254-A1 | Psychological disorders | CINCINNATI, UNIVERSITY OF | 2001-09-20 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| WO-2000053231-A2 | FATTY ACID-ANTICANCER CONJUGATES AND USES THEREOF | PROTARGA, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-2000050020-A2 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5780051-A | Methods and articles of manufacture for nicotine cessation and monitoring nicotine use | DYNAGEN, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| US-4892740-A | DRUG COATED WITH POLYMER SOLUBLE IN GASTRIC JUICE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1990-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11517575-B2 | Use of minaprine to reduce tumor growth | METAP1, METAP2, CMA1 | ACHE 3797/4885CHRM1 4740/4885HTR2B 941/4885 |
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | ACHE 3294/4885CHRM1 1501/4885HTR2B 25/4885 |
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | ACHE 3294/4885CHRM1 1501/4885HTR2B 25/4885 |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | ACHE 2021/4885CHRM1 3136/4885HTR2B 1313/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | ACHE 765/4885CHRM1 2321/4885HTR2B 3638/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | ACHE 403/4885CHRM1 3221/4885HTR2B 1040/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | ACHE 765/4885CHRM1 2321/4885HTR2B 3638/4885 |
| US-20010023254-A1 | Psychological disorders | DRD2, DRD3, DRD1 | ACHE 788/4885CHRM1 400/4885HTR2B 35/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | ACHE 403/4885CHRM1 3221/4885HTR2B 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.